Description
AbbVie Inc. managed to exceed Wall Street’s revenue and earnings expectations, reinforcing a positive trajectory for long-term growth. The recently reported results exemplify this strength, with adjusted earnings per share reaching $2.95, surpassing the guidance midpoint by $0.14. Notably, total net revenues stood at $13.9 billion, exceeding the guidance by approximately $225 million. The ex-HUMIRA growth platform stands out as a powerhouse, achieving remarkable revenue growth of over 12% in the quarter. SKYRIZI and RINVOQ, leading immunology medicines within this platform, contributed to a growth surge of over 50%. The management believes that the combined revenue from these products will surpass HUMIRA’s peak revenues by 2027, with sustained, robust growth anticipated into the next decade. In neuroscience, operational sales experienced a commendable growth rate of over 20%, fueled by a leading portfolio addressing migraine and psychiatric conditions. Aesthetics also demonstrated resilience, marked by the resurgence of the US toxin market. Bolstered by outstanding performance, AbbVie exercised its exclusive right and successfully finalized the acquisition of Mitokinin to strengthen its neuroscience pipeline.
Our Report Structure:
⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures
Want unlimited access to our reports? Purchase our $99 annual subscription!
